SEC Form 4 · accession 0001669396-16-000003
Bausch Health Companies Inc. · BHC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas W. Ross Sr.
Director
Period of report
Jun 13, 2016
Accepted (ET)
Jun 27, 2016 · 3:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885590
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, no par valueF1,F2 | Jun 13, 2016 | P | 4,000 | $24.40 | A | 21,882 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents volume-weighted average price of purchases of 4,000 shares of common stock ('Shares') of Valeant Pharmaceuticals International, Inc. (the 'Company') at prices ranging from $24.37 to $24.41. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of Shares purchased by the reporting person at each separate price within the range set forth in this footnote.
- F2Represents number of Shares beneficially owned as of the filing date.